Payment overview · 2025
General Payments
$149.51
2 reported records · 2 companies
Healthcare provider profile · identity verified
Thomas Pickett
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · CLEARLAKE, CA · NPI 1407494818
Verified facts
What the public records show
CMS Open Payments records show Thomas Pickett received $149.51 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 76.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $114.53 | 76.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.98 | 23.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $149.51 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.53 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 219 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
219 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 759 | 153 |
| Omeprazole | Omeprazole | 497 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 69 |
| Gabapentin | Gabapentin | 406 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 344 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 343 | 57 |
| Metformin Hcl | Metformin Hcl | 316 | 61 |
| Trazodone Hcl | Trazodone Hcl | 260 | 35 |
| Losartan Potassium | Losartan Potassium | 255 | 48 |
| Carvedilol | Carvedilol | 249 | 37 |
| Valsartan | Valsartan | 248 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 58 |
| Ozempic | Semaglutide | 219 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 39 |
| Lisinopril | Lisinopril | 209 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 183 | 32 |
| Montelukast Sodium | Montelukast Sodium | 179 | 39 |
| Furosemide | Furosemide | 152 | 25 |
| Ibuprofen | Ibuprofen | 142 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 20 |
| Jardiance | Empagliflozin | 132 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 24 |
| Potassium Chloride | Potassium Chloride | 122 | 23 |
| Sertraline Hcl | Sertraline Hcl | 116 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 12 |
| Benazepril Hcl | Benazepril Hcl | 105 | 22 |
| Trulicity | Dulaglutide | 98 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 22 |
| Bupropion Xl | Bupropion Hcl | 92 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 17 |
| Famotidine | Famotidine | 88 | 19 |
| Ezetimibe | Ezetimibe | 87 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 15 |
| Baclofen | Baclofen | 80 | 16 |
| Eliquis | Apixaban | 77 | 19 |
| Allopurinol | Allopurinol | 72 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 11 |
| Myrbetriq | Mirabegron | 72 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | suppressed |
| Pregabalin | Pregabalin | 70 | 13 |
| Topiramate | Topiramate | 68 | 16 |
| Alendronate Sodium | Alendronate Sodium | 66 | 16 |
| Celecoxib | Celecoxib | 66 | 20 |
| Finasteride | Finasteride | 66 | 11 |
| Atenolol | Atenolol | 62 | 13 |
| Simvastatin | Simvastatin | 61 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 12 |
| Spironolactone | Spironolactone | 60 | 11 |
| Promethazine Hcl | Promethazine Hcl | 59 | suppressed |
| Entresto | Sacubitril/Valsartan | 58 | suppressed |
| Mirtazapine | Mirtazapine | 57 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Azithromycin | Azithromycin | 52 | 40 |
| Rybelsus | Semaglutide | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | 11 |
| Methylprednisolone | Methylprednisolone | 45 | 22 |
| Ketoconazole | Ketoconazole | 44 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 44 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 16 |
| Ondansetron Odt | Ondansetron | 43 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 12 |
| Meloxicam | Meloxicam | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 21 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | 11 |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Lorazepam | Lorazepam | 27 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 19 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Estradiol | Estradiol | 24 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Niacin Er | Niacin | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Enulose | Lactulose | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vimpat | Lacosamide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $149.51 · 2 records | Novo Nordisk Inc | Ozempic, QULIPTA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error